• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Accession Therapeutics Limited

Monday, June 03, 2024
CP
Oncology
With its stealth virus platform technology, Trocept, Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer. Led by immuno-oncology pioneer Bent Jakobsen, PhD FMedSci, the company is accelerating a pipeline of highly differentiated products towards the clinic. Accession Therapeutics’ Trocept approach enables us to design novel highly targeted treatments with the potential to eradicate all cells in a tumour, regardless of diversity. This enormous increase in the ability to target tumours and wipe out cancer cells eliminates many of the drawbacks of current immunotherapies. We’re the first company to have engineered a viral point of entry to cancer ceIls while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer."
Accession Therapeutics Limited
Company Website: http://www.accessiontherapeutics.com
Lead Product in Development: Trocept 1

Company HQ City

Oxford

Company HQ State

Oxfordshire

Company HQ Country

United Kingdom

CEO/Top Company Official

Bent Jakobsen

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS